Kezar Life Sciences updates drug pipeline, shares trade on Nasdaq

Clinical-stage biotech Kezar Life Sciences has provided fresh detail on its autoimmune and oncology pipeline. The small-cap Nasdaq name remains focused on its lead zetomipzomib program while preparing new data readouts.

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-25, 19:03.

Kezar Life Sciences Inc. (US49374L1008) is a clinical-stage biotechnology company listed on Nasdaq. The company focuses on autoimmune and oncology indications with its lead selective immunoproteasome inhibitor zetomipzomib, as outlined on its investor relations site and recent corporate materials. Kezar Life Sciences investor information

Pipeline focused on zetomipzomib

Kezar Life Sciences describes itself as developing novel, small-molecule therapeutics targeting protein homeostasis for immune-mediated diseases and cancer, with zetomipzomib as its lead candidate. The company highlights that zetomipzomib is a first-in-class selective immunoproteasome inhibitor designed to modulate immune cell function without broad immunosuppression. Company overview of Kezar Life Sciences

According to its pipeline summary, Kezar is studying zetomipzomib in multiple autoimmune indications, including lupus nephritis and other chronic immune disorders, as part of ongoing and planned clinical trials. These programs place Kezar among smaller immunology-focused biotech peers such as Aurinia Pharmaceuticals and Morphic Holding, which also develop therapies for autoimmune kidney and gastrointestinal diseases.

Operations and strategy in clinical development

Kezar Life Sciences is currently positioned as a clinical-stage entity, meaning its drug candidates have not yet reached commercialization and revenue generation. The company reports that it is advancing zetomipzomib in phase 2 studies in autoimmune indications, alongside earlier-stage assets in oncology that target protein degradation pathways. Kezar Life Sciences latest annual report on SEC EDGAR

In its most recent annual filing, Kezar notes that its strategy includes focusing resources on indications where immunoproteasome inhibition could offer meaningful clinical benefit and differentiating on safety compared to broader proteasome inhibitors used in oncology. The company also emphasizes partnerships and disciplined capital allocation as it navigates the costs of clinical trials and regulatory interactions in the United States.

The product behind the stock

The most advanced product candidate at Kezar Life Sciences is zetomipzomib, a selective immunoproteasome inhibitor in clinical trials for autoimmune diseases such as lupus nephritis. The company aims for better immune modulation with a potentially improved safety profile versus broader proteasome inhibition.

The listing and current trading

Kezar Life Sciences Inc. shares trade on Nasdaq in the United States under the ticker KZR. Recent market data show the stock changing hands in the single-digit dollar range, reflecting its status as a small-cap clinical-stage biotech without approved products so far.

Kezar Life Sciences at a glance

• Company: Kezar Life Sciences Inc.
• ISIN: US49374L1008
• WKN: A2JNTU
• Ticker: KZR
• Trading venue: Nasdaq
• Price (as of 2026-06-25, 19:03): not reliably quoted USD
• Market cap: small-cap range USD (as of 2026-06-25)
• Sector / industry: Biotechnology - drug development
• Index membership: not part of major headline indices such as S&P 500 or Nasdaq-100
• Next earnings date: not officially scheduled

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.